Pemetrexed Solution, Concentrate
NDC 0480-4516
Product Information
Pemetrexed is a NDA-approved product labeled by Teva Pharmaceuticals, Inc.. This medication is typically used as a folate analog metabolic inhibitor [epc]. It is supplied as a solution, concentrate for intravenous administration. This product entry covers the primary NDC 0480-4516 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 0480-4516?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- PEMETREXED MONOHYDRATE (UNII: 236Y2F7D9J)
- PEMETREXED (UNII: 04Q9AIZ7NO) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- TROMETHAMINE (UNII: 023C2WHX2V)
- ANHYDROUS CITRIC ACID (UNII: XF417D3PSL)
- METHIONINE (UNII: AE28F7PNPL)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2602363 - PEMEtrexed 500 MG in 20 ML Injection
- RxCUI: 2602363 - 20 ML pemetrexed 25 MG/ML Injection
- RxCUI: 2602363 - pemetrexed (as monohydrate) 500 MG per 20 ML Injection
- RxCUI: 2602365 - PEMEtrexed 1 GM in 40 ML Injection
- RxCUI: 2602365 - 40 ML pemetrexed 25 MG/ML Injection
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.
Patient Education
Pemetrexed Injection
Pemetrexed injection is used in combination with other chemotherapy medications as a first treatment for a certain type of non-small cell lung cancer (NSCLC) that has spread to nearby tissues or to other parts of the body. Pemetrexed injection is also used alone to treat NSCLC as ongoing treatment in people who have already received certain chemotherapy medications and whose cancer has not worsened and in people who could not be treated successfully with other chemotherapy medications. Pemetrexed injection is also in combination with another chemotherapy medication as a first treatment for malignant pleural mesothelioma (a type of cancer that affects the inside lining of the chest cavity) in people who cannot be treated with surgery. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by blocking the action of a certain substance in the body that may help cancer cells multiply.
[Learn More]
* Please review the full disclaimer at the bottom of this page.